Influence
March 21, 2022

Revolutionizing research through pragmatic trials

Revolutionizing research through pragmatic trials

Regenstrief Institute Research Scientist Kathleen Unroe, M.D., MHA, M.S., is at the forefront of the next generation of research methodology: pragmatic trials. Pragmatic trials are designed to evaluate the effectiveness of interventions in real-life practice, speeding up the time from discovery to implementation.  

Dr. Unroe, along with Regenstrief faculty member Susan Hickman, PhD, is leading one of few pragmatic trials funded by the National Institute on Aging. The APPROACHES (Aligning Patient Preferences – a Role Offering Alzheimer’s patients, Caregivers, and Healthcare providers Education and Support) trial is being conducted in 150 nursing homes, testing an intervention to support advance care planning.  

She is also part of the IMPACT Collaboratory, a research incubator to develop pragmatic trials and train researchers to design and execute them.  

In 2021, Dr. Unroe spoke at a conference about pragmatic trials in long-term care facilities. The event identified priorities and best practices for trials taking place in these real-world settings. 

Dr. Unroe says she is excited about the potential of pragmatic trials for creating solutions as well as creating partnerships between researchers and healthcare systems.  

In addition to being a research scientist in the IU Center for Aging Research at Regenstrief Institute, Dr. Unroe is an associate professor at the IU School of Medicine and a practicing geriatrician. 

  • Kathleen Unroe

Related News

National study confirms breakthrough COVID cases are less severe than COVID in unvaccinated adults

National study confirms breakthrough COVID cases are less severe than COVID in unvaccinated adults

Hospitalizations, ICU admissions, and hospital deaths lower for those who are vaccinated and boosted Individuals who, despite having been

April Savoy, PhD

Redesigning diabetes technology to detect low blood sugar in older adults with diabetes and Alzheimer’s disease

Regenstrief Institute Research Scientist April Savoy, PhD, a human factors engineer and health services researcher, is developing and testing

illustration of digestive tract with magnifier and stool sample container

New study provides evidence for three-year interval for multi-target stool DNA screening for those at average risk of colon cancer

A scientific study exploring the appropriate interval for colorectal cancer screening via non-invasive multi-target stool DNA testing for individuals

Dr. Tom Imperiale on tailoring colonoscopy screening for 45- to 49-year-olds

Dr. Tom Imperiale on tailoring colonoscopy screening for 45- to 49-year-olds

Dr. Tom Imperiale explains why physicians should be good stewards of colonoscopy resources.  [button_links href=”https://www.regenstrief.org/article/regenstrief-researcher-calls-for-tailoring-colorectal-cancer-screening-45-49-year-olds/” title=”Read the full